AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04627766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring with VT-Patch (Connected device manufactured by VitalTracer)
Description: Patients will be monitored for 8 consecutive hours and vital signs will be recorded with VT-Patch and with the standard of care
Study NCT04992260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 Vaccine
Description: The inactivated COVID-19 vaccine was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
Study NCT04992260 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Controlled vaccine
Description: The placebo was manufactured by Sinovac Research\& Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
Study NCT05870098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: All participants
Description: 1. Clinician or self-taken, pharyngeal and rectal swabs with FCU analysed individually~2. Self-taken pharyngeal, meatal, and rectal swabs analysed as a pooled specimen~3. Self-taken pharyngeal and rectal swabs with 1.5ml FCU analysed as a pooled specimen The FCU will be done after any meatal swabs. Patients will be instructed to only pass the first 5ml into the tube, and the tube will be pre-marked with a black line. Full pictoral instructions and verbal support will be given to enable them to complete the pooling process of the swabs and urine.
Study NCT05932069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIN
Description: Stationary cycling
Study NCT05932069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-aerobic, stretching/balance intervention Control
Description: Balance and stretching exercise
Study NCT05368233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS protocol
Description: ERAS protocol whch helps to optimise the length of hospital stay.
Study NCT05368233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: ERAS protocol whch helps to optimise the length of hospital stay.
Study NCT04668222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yu-Ping-Feng formula
Description: Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.
Study NCT04668222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiang-Sha-Liu-Jun formula
Description: Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.
Study NCT04668222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liu-Wei-Di-Huang formula
Description: Liu-Wei-Di-Huang formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08273). The intake dosage is 5g twice daily.
Study NCT04668222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Deficiency of Qi and Yang
Description: Placebo for the group of deficiency of Qi and Yang is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula
Study NCT04668222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Deficiency of Qi and Yin
Description: Placebo for the group of deficiency of Qi and Yin is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula
Study NCT06306794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: crochet octopus
Description: During the endotracheal aspiration procedure, the octopus will be given to experimental group 10 minutes before the procedure.
Study NCT05084534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by >10% (maximum dose - 15mg/day)~• Midodrine dosage will be decreased by 25% in case of arterial hypertension (>95th centile BP for the age)
Study NCT05084534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard Medical Treatment will be continued in all, which includes,~* To continue restriction of sodium to \< 2meq/kg/day~* To continue maximum tolerable dose of diuretics~* Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~* Albumin infusion for serum albumin \<2.5g/dl - dose 1g/kg/day (maximum 20g/day)
Study NCT05084534 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard medical treatment
Description: Standard Medical Treatment will be continued in all, which includes,~* To continue restriction of sodium to \< 2meq/kg/day~* To continue maximum tolerable dose of diuretics~* Repeat LVP with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~* Albumin infusion for serum albumin \<2.5g/dl - dose 1g/kg/day (maximum 20g/day)
Study NCT04905719 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Each patient included to the study will undergo Point-of-Care ultrasound testing specific for the area defined in the Groups section.
Study NCT05485857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arrangement of small intestine order before close the abdomen
Description: After the completion of laparoscopic-assisted colorectal cancer surgery, the chief surgeon performed laparoscopic small bowel arrangement before closing the abdomen, straightening the small bowel from the colon-small bowel anastomosis or the ileocecal valve to the ligament of Trevor, and restoring the original position of the small bowel. Afterward, close the abdomen.
Study NCT06330428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexuality-Based Family Planning Education via Podcast
Description: The training program is planned to consist of 5 modules. These trainings will be shared module by module on a daily basis through an application (Spotify) where podcasts are shared. These modules are as follows: 1. Sexual and Reproductive Health / Sexual Rights / Female-Male / Physiology of Sexual Functions, 2. Sexual Myths, 3. Contraceptive Methods-1, 4. Contraceptive Methods-2, 5. Sexually Transmitted Diseases / Safe Sexual Intercourse As a result of randomization, the links of the podcasts will be shared with the women in the experimental group one by one on a daily basis. Podcasts are planned to last an average of 10 minutes. This training content is planned for 5 days and the second tests will be applied by the researcher to the women who finish the podcasts. The 3rd tests will be applied 4 weeks after the second tests.
Study NCT06452823 — intervention group
Intervention type: PROCEDURE
Intervention: Catheter Ablation
Description: catheter radiofrequency ablation therapy for atrial fibrillation involves the use of ablative energy to destroy the cardiomyocytes at the opening of the pulmonary veins, which blocks the electrical conduction pathway between the pulmonary veins and the left atrium, so that atrial fibrillation no longer occurs.
Study NCT05469893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Intravenous (IV) dosage and timing per protocol design
Study NCT04452461 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX, including: Oxaliplatin 85 mg/m2 IV over 2 hours, Leucovorin 400mg/m2 IV over 2 hours, Irinotecan at 150 mg/m2 IV over 90 min, 5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h.
Study NCT04452461 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine / Nab-paclitaxel
Description: Both drugs are administered once weekly for three weeks (days 1, 8, 15) followed by a week of rest (28-day cycle) for 3 cycles prior to imaging. Gemcitabine: 1000 mg/m2 intravenous infusion over 30 to 40 minutes. Nab-paclitaxel: 125 mg/m2 intravenous infusion over 30 to 40 minutes.
Study NCT06054724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga-Based Respiration Training
Description: The selected asanas, believed to be beneficial for urinary incontinence, will be practiced with a focus on breath. After the assessment session, participants will engage in three days of face-to-face yoga sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
Study NCT06054724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates-Based Respiration Training
Description: Before starting the 6-week practice protocol, participants will be taught the transversus abdominis muscle activation and centering, pilates-specific lateral costal breathing and other key elements of pilates. Pilates exercises chosen as beneficial for urinary incontinence will be performed with a focus on breath. After the assessment session, participants will engage in three days of face-to-face pilates sessions. On the days when face-to-face sessions are held, participants will perform the second session on their own at home. The exercises will be progressively intensified during the 3rd and 5th weeks to ensure progression. The exercise program will be conducted at home, with approximately 20-minute sessions, twice a day, five days a week, for a total of 6 weeks.
Study NCT06038721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children
Description: The UP-C is administered in-person to parents and children over the course of up to 15 weekly group sessions, which last approximately 90 minutes each.
Study NCT06038721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents
Description: The UP-A is administered to parents and teens over the course of approximately 15-24 weekly individual sessions, which last approximately 50 minutes each. Sessions can be administered in-person or online, with at least one session occurring in person.
Study NCT06635317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100 mg/day orally for 25 days
Study NCT06635317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: 40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².
Study NCT06635096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal Tumor Thermal Therapy System (Shanghai MAaGI Medical Technology Co., Ltd.)
Description: These patients will receive multimodal thermal therapy using Multimodal Tumor Thermal Therapy System.
Study NCT06634628 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [11C]CHDI-00491009
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.
Study NCT05304884 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: combined oxygen-ozone and corticosteroid
Description: Subacromial injection using Ultrasound
Study NCT06644391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Carebot AI Bones
Description: The use of a deep learning-based artificial intelligence software, Carebot AI Bones version 1.2.2, designed to aid in the detection of fractures on musculoskeletal radiographs. The AI model analyzes digital X-ray images to identify fractures, highlighting areas of interest with bounding boxes.
Study NCT05191225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection [Truxima]
Description: 375 (mg/m2) / 60 minutes
Study NCT05191225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection [Truxima]
Description: 375 (mg/m2) / 30 minutes
Study NCT06013020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC+DAPT
Description: Century Clot-guided rivaroxaban plus DAPT.
Study NCT06013020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT
Description: Standard DAPT for 1 month, following lower-dose ticagrelor or clopidogrel plus aspirin for 11 months.
Study NCT06069765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TUPEX
Description: This program contains exercises with their own body weight or with Thera-bands for gaining strength in their shoulder and trunk muscles. It contains some progression exercise if needed.~Each session can last between 20 and 30 minutes. Children have to do each session three times a week during 8 weeks.
Study NCT05745064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TL-925
Description: TL-925 is an eye drop.
Study NCT05745064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Study NCT05469893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Oral, dosage and timing per protocol design
Study NCT05469893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral, dosage and timing per protocol design
Study NCT05374317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine
Description: Administered subcutaneously once.
Study NCT05374317 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever Vaccine
Description: Administered subcutaneously once.
Study NCT06542848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and Rehabilitation Practices
Description: The treatment program consisted of 3 sessions per week, each lasting 45 minutes. The rehabilitation program included 30 minutes of conventional TENS application to the wrist extensor muscles and quadriceps muscle, upper and lower extremity exercises, balance and coordination exercises, and weight transfer exercises. The upper extremity exercises consisted of range of motion exercises for the shoulder joint, while the lower extremity exercises included range of motion exercises for the hip, knee, and ankle joints. Balance exercises included forward, backward, and lateral leaning exercises, as well as weight transfer and stepping exercises in all directions. The treatment duration was planned to be a total of 24 sessions over 8 weeks. Evaluations were conducted before and after the treatment program.
Study NCT04725721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIRST
Description: FIRST is built upon five empirically supported principles of change (ESPCs-i.e., feeling calm, increasing motivation, repairing thoughts, solving problems, trying the opposite). Each principle can be applied to treatment of problems spanning depression, anxiety (including OCD and PTS), and conduct problems-thus encompassing a majority of the youths seen in outpatient care. Its design addresses breadth of problem coverage, youth comorbidity, and flux in youth treatment needs during episodes of care. It is used in conjunction with performance feedback via a web-based tracking system that gives clinicians weekly data on youth treatment response. FIRST has treatment and training efficiency, and efficient clinician skill-building is supported by group consultation.
Study NCT04725721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Treatment in the usual care (UC) condition will use the clinical procedures therapists consider appropriate and believe to be effective.
Study NCT04724655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gastric lavage with paraffin oil and bicarbonate
Description: Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube
Study NCT05426252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept, co-stimulation blockade, to be given for GVHD prophylaxis in combination with sirolimus post allogeneic hematopoietic stem cell transplantation.
Study NCT05426252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus, mTOR inhibitor, to be given for GVHD prophylaxis in combination with abatacept post allogeneic hematopoietic stem cell transplantation.
Study NCT05841381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: pyrotinib: 400mg orally daily for 1 year
Study NCT05841381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles
Study NCT05841381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles
Study NCT05841381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 per week for a total of 12 weeks
Study NCT05841381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 per week for a total of 12 weeks
Study NCT06085482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally
Study NCT06085482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3502970
Description: Administered IV
Study NCT04198350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet implantation
Description: Transplantation of allogeneic pancreatic human islets will be performed into the anterior chamber of a single eye with the poorest visual acuity (see inclusion/exclusion criteria below). Up to 40 000 IEQ of islets in a maximum volume of 350µl will be transplanted.
Study NCT04933669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib neoadjuvant therapy
Study NCT05653050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX
Description: Fully automated closed-loop system (CamAPS HX) with ultra-rapid insulin aspart.
Study NCT05653050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin pump therapy with CGM
Description: Participants usual insulin pump therapy with Freestyle Libre 3 CGM
Study NCT05959057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ERr 731 - Micro-coated
Description: natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
Study NCT05959057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ERr 731 - Enteric coated
Description: natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
Study NCT03284073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus transplantation
Description: Transplantation of the uterus from a live donor and IVF treatment
Study NCT06536920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Migraine screening questionnaire
Description: Screening test
Study NCT06536829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofacial release technique and sciatic nerve slider technique
Description: Myofacial release technique, sciatic nerve slider technique 0 week,6 week 12 weeks
Study NCT06536829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofacial release technique
Description: 0week,6 week, 12 weeks
Study NCT06542328 — intervention group
Intervention type: DEVICE
Intervention: ERI CVX-air portable X-ray system
Description: investigational device
Study NCT06542328 — intervention group
Intervention type: DEVICE
Intervention: Samsung GM85 (K180543) or MobileDaRt Evolution (K080701)
Description: The commercially available comparator equipment used for pulmonology.
Study NCT06542328 — intervention group
Intervention type: DEVICE
Intervention: Samsung GC85A (K160997) or Fujifilm FDR Smart X (K212956)
Description: The commercially available comparator equipment used for Orthopaedic.
Study NCT05433818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: Skin-to-Skin Contact (SSC) contributes to mother-infant interaction and can increase breastfeeding success
Study NCT05433818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: education with a structured and expert opinion-based breastfeeding brochure
Study NCT04724655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gastric lavage with coconut oil and bicarbonate
Description: Gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube
Study NCT04724655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
Study NCT04724655 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: standard treatment
Description: inotropes as levophid, fluids and electrolytes , endotracheal intubation, mechanical ventilation and antiarrhythmic agents as Magnesium sulfate
Study NCT04724655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: gastric lavage with saline and bicarbonate
Description: Gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube
Study NCT05212974 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: The questionnaires include demographic data and vaccine hesitancy questions in a total of 35 items.
Study NCT06100926 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: software
Description: virtual reality scene